Teva api Presents New Opportunities with Customers at CPhI Japan 2016
Koby Toby, Representative Director and President of teva api Japan
Tokyo served as the setting for the CPhI pharmaceutical show last month, welcoming the teva api Japan team and thousands of other industry professionals to CPhI Japan. This exhibition is the country’s premier industry event, drawing decision makers from Japan-based pharmaceutical companies and global organizations who do business in the country.
For Teva api, this event presented the perfect opportunity to spend time with our customers to discuss current projects and give them a preview of products in development. Teva api's top professionals from R&D, technical support, supply chain and customer experience joined our account managers to provide detailed updates and for a collaborative discussions. Customers shared an enthusiastic response to their personal in-depth introductions to the more than 20 new products to the Japanese market over the next few years.
The products teva api introduced for the Japanese market during CPhI Japan, 2016 include the following generic launches prospected* for the Japanese market - You are welcome to contact us with questions regarding each product :
Bortezomib, Mirtazapine, Mometasone Furoate, Eszopiclone, Ezetimibe, Febuxostat, Galantamine HBr, Caspofungin Acetate, Fulvestrant, Pregabalin, Sitagliptin, Azacitidine, Rotigotine, Abiraterone Acetate, Palonosetron HCI, Nilotinib HCI
During the three-day event, we welcomed a steady stream of attendees to our booth, which was designed with a Koinobori theme. Koinobori, or Japanese carp streamers, are wind socks traditionally flown in Japan from April to early May to celebrate Children's Day – a national holiday when families celebrate the health and happiness of their children. Among our booth activities, we hosted a well-attended information session led by one of TAPI’s top R&D scientists, Dr. Edi Schwartz, who discussed teva api's commitment to R&D and the future of product development for the Japanese market. Teva api has more than 800 scientists worldwide who are dedicated to developing new products and processes. Our R&D knowledge and support helps customers stay ahead in the Japanese marketplace with focus on quality, on time and superb offerings.
CPhI Japan was an opportunity for teva api to introduce its coming new President, Gil Feldman, as teva api Japan undergoes a management transition over the next two months. Ensuring a seamless transition for customers, both the outgoing and incoming executives met with customers during the conference. Gil Feldman is finishing a three-year assignment for teva api in the United States and will succeed Koby Toby in teva api’s Tokyo office as Representative Director and President of Teva api Japan beginning in July.
Come by and meet with the teva api team at these upcoming events: CPhI China, 21-23 June 2016